Abbott Labs Sells Developed Markets Generics Unit

July 14 (Bloomberg) -- Marshall Sonenshine, chairman and managing partner at Sonenshine Partners, and Jonathan Golub, chief U.S. market strategist at RBC Capital Markets, examine Abbott Laboratories selling its developed markets generic drug unit to Mylan in a deal worth $5.3 Billion and what it means to the current M&A market. They speak on “Bloomberg Surveillance.”
When Will the Fed Raise Rates?
39:54 - Rabobank Senior FX Strategist Jane Foley discusses U.S. interest rates and the euro-dollar trade. She speaks to Bloomberg’s Anna Edwards on “Countdown.” (Source: Bloomberg)
  • A Deal With Iran Is More Likely Than Not: Soltvedt
  • Role of ECB in the Crisis Is Very Crucial: Foley
  • Ace to Buy Chubb for $28.3B